Amgen's Repatha Wins CHMP Nod for Broader Cardiovascular Risk Prevention — Amgen Inc.

Event summary

The CHMP adopted a positive opinion for Amgen's Repatha (evolocumab) to reduce cardiovascular risk in high-risk adults without prior heart attack or stroke.
The recommendation is based on the Phase 3 VESALIUS-CV trial, which showed a 25% relative reduction in major adverse cardiovascular events (MACE).
Repatha demonstrated a 36% reduction in the risk of heart attack and significantly lowered LDL-C levels in the trial.
The European Commission is expected to make a final decision on the application in the coming months.

The big picture

The CHMP's positive opinion for Repatha underscores the growing emphasis on preventive cardiovascular care, particularly for high-risk patients without prior events. This strategic shift aligns with broader industry trends toward early intervention in cardiometabolic diseases. Amgen's success with Repatha positions it to capitalize on the expanding market for lipid-lowering therapies, potentially redefining cardiovascular risk management in Europe.

What we're watching

Regulatory Approval Timing: The pace at which the European Commission finalizes its decision on Repatha's expanded indication will determine market access and revenue potential.
Competitive Positioning: Whether Amgen can leverage this approval to solidify Repatha's leadership in the PCSK9 inhibitor market against emerging therapies.
Commercialization Strategy: How Amgen plans to address the unmet need in Europe, where many high-risk patients remain above recommended LDL-C targets despite available therapies.